BridgeBio's drug for genetic condition meets main goals in late-stage study
29/10/2025 11:05
Oct 29 (Reuters) - BridgeBio Pharma BBIO.O said on Wednesday that its experimental drug for a genetic condition that causes low blood calcium met all the main and secondary goals in a late-stage study. (Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Sahal Muhammed) ((Padmanabhan.Ananthan@thomsonreuters.com;))
Recent news on BridgeBio Pharma
See all newsU.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
BridgeBio rises on FDA priority review for dwarfism drug
Brief: Bridgebio Announces FDA Acceptance And Priority Review Of NDA For Oral Infigratinib For Children With Achondroplasia
Brief: Bbp-418 Demonstrates Potential To Be Disease Modifying Therapy, Restoring Cardiac And Disease Markers To Unaffected Levels